Mon, Apr 21, 2014, 11:23 AM EDT - U.S. Markets close in 4 hrs 37 mins

Recent

% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

  • Rob_Cos Rob_Cos Aug 23, 2007 9:24 AM Flag

    Out this am-Zacks currently recommending SGMO!

    News Story

    Zacks Analyst Interview Highlights: Lexicon Pharmaceuticals, Critical Therapeutics and Sangamo Biosciences

    6:00 AM EDT August 23, 2007
    CHICAGO--(BUSINESS WIRE)--

    Zacks.com releases the latest Analyst Interview. Today's interview is with senior analyst Grant Zeng, who discusses Lexicon Pharmaceuticals (Nasdaq: LEXG), Critical Therapeutics (Nasdaq: CRTX) and Sangamo Biosciences (Nasdaq: SGMO).

    A synopsis of today's Analyst Interview is presented below. The full article can be read at http://at.zacks.com/?id=2678.

    Have biotech firms in your coverage been affected by the recent broad-market sell-off?

    The recent broad market sell-off triggered by the sub-prime mortgage crisis has limited impact on biotech firms at least for the firms in my coverage. This is understandable, since the biotech industry in general is event-driven due to its early stage of development. Instead of looking for top line growth, investors are more concentrated on clinical development, market potential for pipeline candidates and cash positions of biotech companies.

    What specific Buy recommendations in biotech do you currently have?

    I have quite a few Buy recommendations under my coverage. These names include Lexicon Pharmaceuticals (Nasdaq: LEXG), Critical Therapeutics (Nasdaq: CRTX) and Sangamo Biosciences (Nasdaq: SGMO), to just name a few.

    Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2679.

    About Zacks

    Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros by going to http://at.zacks.com/?id=2648.

    Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

    (a)The Zacks Performance Rank performance is the total return of equal weighted simulated portfolios consisting of those stocks with the indicated Zacks Rank net of fees. Results reflect the reinvestment of dividends and other earnings. Simulated results do not represent actual trading and may not reflect the impact that economic and market factors might have had on decision-making if an adviser were actually managing a client's money.

    (b)The S&P 500 Index ("S&P 500") is a well-known, unmanaged index of the prices of 500 large-company common stocks selected by Standard & Poor's. The S&P 500 includes the reinvestment of all dividends, no transaction costs, and represents the gross returns before management fees.

    Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

    Source: Zacks.com

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGMO
14.04+0.05(+0.36%)11:22 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.